Literatur
2016a). Hepatitis C among drug users in Europe: epidemiology, treatment and prevention. EMCDDA Insights Series No 23. Luxembourg: Publications Office of the European Union. Abgerufen unter http://www.emcdda.europa.eu/publications/insights/hepatitis-c-among-drug-users-in-europe
(2016b). Annual report 2016: The state of the drugs problem in Europe. Luxembourg: Publications Office of the European Union. Abgerufen unter http://www.emcdda.europa.eu/edr2016
(2013). Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 57 (Suppl. 2), S39–S45.
(2016). Prioritization of HCV treatment in the direct–acting antiviral era: An economic evaluation. Journal of Hepatology, 65, 17 – 25
(Rat der Europäischen Union. (2015)
Schlussfolgerungen des Rates zur Umsetzung des Drogenaktionsplans der EU (2013 – 2016) bezüglich der Mindestqualitätsstandards bei der Verringerung der Drogennachfrage in der Europäischen Union. CORDROGUE 70, Dokument ST 11985 2015 INIT. Abgerufen unter http://data.consilium.europa.eu/doc/document/ST-11985 – 2015-INIT/de/pdf 2014). Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. PLoS One, 9(7), e103345.
(2016). Global health sector strategy on viral hepatitis 2016 – 2021. Towards ending viral hepatitis. Geneva: Autor. Abgerufen unter http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1
(